Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: This study aimed to evaluate the utility of the albumin-bilirubin grade for predicting the prognosis after repeat liver resection for patients with recurrent hepatocellular carcinoma.
Patients And Methods: Ninety patients with intrahepatic recurrent hepatocellular carcinoma who underwent repeat liver resection at our institution between 2005 and 2019 were retrospectively analyzed. Cox proportional-hazards regression models evaluated independent preoperative prognostic factors, including the albumin-bilirubin grade. Prognosis differences between patients with albumin-bilirubin grades 1 and 2 were analyzed using the Kaplan-Meier method.
Results: Cox proportional-hazards regression analysis revealed that albumin-bilirubin grade 2 (p=0.003) and early recurrence within one year from the initial surgery (p=0.001) were independently associated with poor recurrence-free survival, and albumin-bilirubin grade 2 (p=0.020) was independently associated with poor overall survival. The five-year recurrence-free (31% and 17%, respectively) and overall (86% and 60%, respectively) survival rates after repeat liver resection for patients with albumin-bilirubin grades 1 and 2 were significantly different between groups (both p=0.003).
Conclusion: The albumin-bilirubin grade is useful for preoperatively predicting favorable survival rates after repeat liver resection for patients with recurrent hepatocellular carcinoma. Patients with an albumin-bilirubin grade 1 are better candidates for surgical treatment of recurrent hepatocellular carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.17006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational study.
Eur J Radiol
September 2025
Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. Electronic address:
Objectives: Preoperatively identifying patients with unresectable hepatocellular carcinoma (uHCC) who are likely to achieve an objective response to the treatment regimen of transarterial chemoembolization (TACE) plus lenvatinib and programmed death-1 inhibitors (TLP) remains challenging. We aimed to develop and validate a predictive model for tumor response to TLP treatment in patients with uHCC.
Materials And Methods: Patients with uHCC who received TLP treatment were divided into training (n = 107), internal validation (n = 46), and external validation (n = 52) cohorts.
Classification of liver lesions based on temporal changes in hepatobiliary phase contrast on magnetic resonance imaging: a preliminary study.
Radiol Phys Technol
September 2025
Division of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa, Ishikawa, 920-0942, Japan.
This study evaluated whether temporal changes from the dynamic late phase to the hepatobiliary phase using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid supported liver tumor classification. A total of 147 patients with 165 lesions (hepatocellular carcinoma [HCC], metastases, and hemangiomas) underwent 3.0 T MRI.
View Article and Find Full Text PDFEfficacy and Safety Analysis of Transarterial Chemoembolization Combined with Sintilimab Plus Bevacizumab Biosimilar in the Treatment of Unresectable Hepatocellular Carcinoma.
J Hepatocell Carcinoma
August 2025
Department of Hepatobiliary Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541001, People's Republic of China.
Background: Transarterial chemoembolization (TACE) remains a cornerstone for unresectable hepatocellular carcinoma (uHCC) but is limited by tumor progression. Combining TACE with systemic therapies may enhance efficacy. Notably, sintilimab combined with bevacizumab biosimilar has shown synergistic effects in tumor control and has been incorporated into the first-line treatment regimen in China.
View Article and Find Full Text PDFAssociation of ALBI Grade, APRI Score, and ALBI-APRI Score with Postoperative Outcomes among Patients with Liver Cirrhosis after Non-hepatic Surgery.
Acta Med Philipp
July 2025
Division of Internal Medicine, National Kidney and Transplant Institute, Quezon City, Philippines.
Background And Objective: Patients with liver cirrhosis have an increased risk for poor postoperative outcomes after non-hepatic surgery, with liver dysfunction being the most important predictor of poor outcomes. This study aims to determine the association of the albumin-bilirubin (ALBI) grade, aspartate aminotransferase-platelet ratio index (APRI) score, and ALBI-APRI score with postoperative outcomes among cirrhotic patients who have undergone non-hepatic surgery.
Methods: This was a retrospective cohort study involving 34 patients.
Albumin-bilirubin (ALBI) and Platelet-ALBI (PALBI) Grades: Novel Prognostic Factors for Cholangiocellular Carcinoma.
In Vivo
August 2025
Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Türkiye.
Background/aim: Cholangiocarcinoma (CCA) is the second most frequently occurring primary malignant tumor of the liver, characterized by poor survival due to late diagnosis and limited treatment options. The albumin-bilirubin (ALBI) and platelet-ALBI (PALBI) scores, which reflect liver function and inflammation, have emerged as potential prognostic markers in hepatocellular carcinoma (HCC). Their prognostic significance in CCA, however, remains less established.
View Article and Find Full Text PDF